{"id":1085,"date":"2025-07-20T00:07:20","date_gmt":"2025-07-20T00:07:20","guid":{"rendered":"https:\/\/mediwhale.stage.studio-jt.co.kr\/kr\/?post_type=publication&#038;p=1085"},"modified":"2025-07-20T00:07:20","modified_gmt":"2025-07-20T00:07:20","slug":"ai-based-noninvasive-retinal-imaging-for-ckd-risk-prediction-in-dm-patients-without-established-ckd","status":"publish","type":"publication","link":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/publication\/ai-based-noninvasive-retinal-imaging-for-ckd-risk-prediction-in-dm-patients-without-established-ckd\/","title":{"rendered":"AI-Based Noninvasive Retinal Imaging for CKD Risk Prediction in DM Patients without Established CKD"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">I<strong>ntroduction and Objective:<\/strong>\u00a0<\/h4>\n\n\n\n<p>Dr.Noon CKD is a deep-learning model analyzing retinal images to predict the likelihood of eGFR \u2264 60mL\/min\/1.73m\u00b2 (reti-eGFR) and estimate 5-year CKD risk using age, sex, and reti-eGFR in a Cox regression model. This study evaluates its utility in DM patients without CKD by comparing CKD risk predictions between hypertensive and normotensive patients.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Methods:<\/strong>\u00a0<\/h4>\n\n\n\n<p>After excluding patients with CKD (eGFR \u2264 60 or UACR \u2265 30mg\/g), UK Biobank data were used for 1:1 propensity score matching. Matching criteria included age, sex, UACR, BMI, LDL-C, HDL-C, BP, and smoking status for reti-eGFR and eGFR analyses. For 5-year CKD risk prediction, age and sex were excluded from the criteria. Dr.Noon CKD scores were averaged across both eyes. Statistical analyses included Wilcoxon rank-sum tests, Holm-adjusted p-values, and odds ratios (OR) with 95% confidence intervals (CI).<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Results:<\/strong><\/h4>\n\n\n\n<p>\u00a0While eGFR values were similar between groups, hypertensive patients had higher reti-eGFR and Dr.Noon 5-year CKD risk scores, as shown in\u00a0<em>Figure 1<\/em>. The 5-year CKD risk score (OR: 4.19, 95% CI: 1.19-15.12) and reti-eGFR (OR: 3.70, 95% CI: 1.15-12.16) were strong predictors, with males showing higher risk than females (OR: 1.55, 95% CI: 1.08-2.23).<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Conclusion:<\/strong>\u00a0<\/h4>\n\n\n\n<p>In DM patients without CKD, Dr.Noon CKD offers a non-invasive approach for CKD risk stratification, complementing eGFR in identifying risk differences.<\/p>\n","protected":false},"template":"","publication_type_categories":[12],"publication_categories":[17],"class_list":["post-1085","publication","type-publication","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication\/1085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/types\/publication"}],"version-history":[{"count":1,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication\/1085\/revisions"}],"predecessor-version":[{"id":1086,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication\/1085\/revisions\/1086"}],"wp:attachment":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/media?parent=1085"}],"wp:term":[{"taxonomy":"publication_type_categories","embeddable":true,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication_type_categories?post=1085"},{"taxonomy":"publication_categories","embeddable":true,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication_categories?post=1085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}